Chronic urticaria in children under 15 years of age: Clinical experience beyond the clinical trials

Oriol Corral-Magaña1, José Antonio Gil-Sánchez2, Catalina Bover-Bauzá3

  • 1Department of Dermatology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.

Pediatric Dermatology
|January 7, 2021
PubMed

Insights

Pediatric chronic urticaria (CU) in Spain presented similarly to adult cases, with most children responding well to H1-antihistamines. Further research is needed to establish specific pediatric treatment guidelines.

Area of Science:

  • Pediatric Dermatology
  • Allergy and Immunology

Background:

  • Chronic urticaria (CU) is a challenging condition in children.
  • Understanding its clinical profile and management in pediatric populations is crucial.

Purpose of the Study:

  • To describe the clinical characteristics, management strategies, and outcomes of pediatric patients diagnosed with chronic urticaria.
  • To evaluate the effectiveness of current treatment protocols in children.

Main Methods:

  • Retrospective study of children under 15 years diagnosed with CU between 2014 and 2019.
  • CU defined as persistent wheals and/or angioedema for over 6 weeks.
  • Data collected on patient demographics, triggers, comorbidities, and treatment responses.

Main Results:

  • Twenty-nine pediatric patients (mean age 8 years, 17 girls) were included.
  • 31% had a family history of atopy; 41.3% experienced associated angioedema.
  • Most cases responded to standard or doubled doses of H1-antihistamines; omalizumab was effective in refractory cases.

Conclusions:

  • Pediatric CU shares similarities with adult CU, including female predominance and links to atopy.
  • Current treatment guidelines for adults are applied to children, highlighting a need for pediatric-specific assessment tools and treatment strategies.
Abstract

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
30.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
109
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
4.5K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89